AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Keros Therapeutics, Inc. Director's Dealing 2021

Jan 12, 2021

32602_dirs_2021-01-12_be6a625f-0edc-4418-b367-2b27cae31227.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Keros Therapeutics, Inc. (KROS)
CIK: 0001664710
Period of Report: 2021-01-10

Reporting Person: Regnante Keith (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-01-10	Employee Stock Option (right to buy)	$70.93	A	49150	Acquired	2031-01-09	Common Stock (49150)	Direct

Footnotes

F1: One-fourth (1/4th) of the shares subject to the option shall vest on January 7, 2022, and one-twelfth (1/12th) of the remaining shares subject
to the option shall vest in equal quarterly installments thereafter, subject to the Reporting Person continuing to provide service through each such
date.